Form 4 for RIGL RIGEL PHARMACEUTICALS INC
Accepted 2025-05-28 00:00:00 ET · period of report 2025-05-23 · accession 0000905148-25-001933 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-28 | 2025-05-23 | RIGL | LAPOINTE ANTHONY GREGG | Dir | A - Grant | $0.00 | +2,500 | 12.5K | +25% | $0 |
| D | 2025-05-28 | 2025-05-23 | RIGL | LAPOINTE ANTHONY GREGG | Dir | A - Grant | $0.00 | +3,000 | 3,000 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-23 | A | A | 2,500 | $0.00 | 12,500 | D | — | — | (F1) The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. (F2) This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-05-23 | A | A | 3,000 | $0.00 | 3,000 | D | $18.95 · — to 2035-05-23 | 3,000 Common Stock | (F3) The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. |